Details

Autor(en) / Beteiligte

• Hagemann, Christoffer A.
• Jensen, Malene S.
• Holm, Stephanie
• Gasbjerg, Lærke S.
• Byberg, Sarah
• Skov-Jeppesen, Kirsa
• Hartmann, Bolette
• Holst, Jens J.
• Dela, Flemming
• Vilsbøll, Tina
• Christensen, Mikkel B.
• Holst, Birgitte
• Knop, Filip K.

Titel

LEAP2 reduces postprandial glucose excursions and ad libitum food intake in healthy men

Ist Teil von

• Cell reports. Medicine, 2022-04, Vol.3 (4), p.100582-100582, Article 100582

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2022

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• The gastric hormone ghrelin stimulates food intake and increases plasma glucose through activation of the growth hormone secretagogue receptor (GHSR). Liver-expressed antimicrobial peptide 2 (LEAP2) has been proposed to inhibit actions of ghrelin through inverse effects on GHSR activity. Here, we investigate the effects of exogenous LEAP2 on postprandial glucose metabolism and ad libitum food intake in a randomized, double-blind, placebo-controlled, crossover trial of 20 healthy men. We report that LEAP2 infusion lowers postprandial plasma glucose and growth hormone concentrations and decreases food intake during an ad libitum meal test. In wild-type mice, plasma glucose and food intake are reduced by LEAP2 dosing, but not in GHSR-null mice, pointing to GHSR as a potential mediator of LEAP2’s glucoregulatory and appetite-suppressing effects in mice. [Display omitted] •Exogenous LEAP2 lowers postprandial plasma glucose excursions•Exogenous LEAP2 suppresses ad libitum food intake•During fasting, exogenous LEAP2 increases insulin secretion and suppresses lipolysis•The GHSR is required for eliciting LEAP2 effects in mice LEAP2 was recently discovered as a hormone in rodents, which modulates ghrelin actions on plasma glucose and appetite. In a randomized, double-blind, placebo-controlled trial, Hagemann et al. demonstrate that exogenous LEAP2 reduces postprandial glucose excursions and food intake in healthy men.